Pediatric fever of uncertain source: Difference between revisions
 
(256 intermediate revisions by 16 users not shown)
Line 1: Line 1:
== From Tintinalli ==
==Background==
*Fever accounts for 30% of pediatric visits
*Children <3 months are immunocompromised (e.g. poor opsonization, poor IgG response to encapsulated bacteria, macrophage and neutrophil dysfunction, bone marrow insufficiency)


'''Management of patients who are well-appearing, vaccinated, and no clinical source of fever'''  
===Epidemiology and Risk===
 
{| class="wikitable"
{| style="width: 500px" cellspacing="1" cellpadding="1" border="1"
| align="center" style="background:#f0f0f0;"|'''Age'''
| align="center" style="background:#f0f0f0;"|'''0-14 days'''
| align="center" style="background:#f0f0f0;"|'''14-28 days'''
| align="center" style="background:#f0f0f0;"|'''28-60 days (pre vaccine)'''
| align="center" style="background:#f0f0f0;"|'''28-60 days (post vaccine)'''
| align="center" style="background:#f0f0f0;"|'''60-90 days'''
| align="center" style="background:#f0f0f0;"|'''> 90 days'''
|-
|-
| Age Group
| [[Meningitis]]/SBI Prevalence ||1/10||1/20||1/100||1/1000||1/1000-10,000||> 1/10,000
| Evaluation
|}
| Treatment
*Serious bacterial illness (SBI) includes UTI, meningitis, pneumonia, bacteremia
|-
*7% of patients <2 years old with fever have [[pneumonia]], however the etiology (viral/bacterial) or even the presence of pneumonia has low inter-observer reliability even among pediatric radiologists<ref>ACEP's Clinical Policy on Pediatric Fever. Clinical Policy for Children Younger Than Three Years Presenting to the Emergency Department With Fever. Annuals of Emergency Medicine 2003 42. 530-545</ref>
|
*4% Prevalence of [[UTI]] with common other sources of fever ([[OM]], viral [[URI]], etc)<ref>ACEP's Clinical Policy on Pediatric Fever. Clinical Policy for Children Younger Than Three Years Presenting to the Emergency Department With Fever. Annuals of Emergency Medicine 2003 42. 530-545</ref>
0-28d, ≥38C
*0.3% of previously well children aged 3-36 months who have a fever without a source will develop significant sequelae, 0.03% will develop sepsis or meningitis<ref>ACEP's Clinical Policy on Pediatric Fever. Clinical Policy for Children Younger Than Three Years Presenting to the Emergency Department With Fever. Annuals of Emergency Medicine 2003 42. 530-545</ref>


SBI incidence of ill appearing: 13%–21%  
===Concomitant Respiratory Viral Infection===
*Relatively high coincidence of [[RSV]], [[enterovirus]], and [[paraflu]] with bacteremia (and UTIs), so positive lab test for these viruses should not change testing and management plan<ref>Greenes, D.S.M., & Harper, M. B.M. (1999). Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatric Infectious Disease Journal, 18(3), 258-261.</ref>
**[[RSV]]+ neonates aged 0-28 days, 3.7% were bactremic (and 6.1% had [[UTI]]s)
**RSV+ infants aged 29-60 days, (5.5% had [[UTI]]s)
*There is a low coincidence of [[influenza]] with SBI, so postivie lab test for this virus may change testing and management plan (i.e. lower risk of concurrent bacterial illness)<ref>Greenes, D.S.M., & Harper, M. B.M. (1999). Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatric Infectious Disease Journal, 18(3), 258-261.</ref>


if not ill appearing: &lt;5%
==Clinical Features==
*[[Acute fever|Febrile]]
**Defined as [[Celsius Fahrenheit Temperature Conversion|temperature]] ≥38°C (100.4°F).
**Peripheral temperature is not clinically accurate and central measurements are the preferred means of determining fever.
**Parental report of confirmed fever at home (i.e. via thermometer), even with no fever in ED, has rates of SBIs high as 4.7% (0-28 day range)<ref>Serious bacterial infections in neonates presenting afebrile with history of fever Ramgopal S, Walker LW, Tavarez MM, et al. Pediatrics. 2019;144(2):e20183964.</ref>


|
==Differential Diagnosis==
CBC, blood Cx
{{Pediatric fever DDX}}


UA, Ucx
==Evaluation & Management==
*Preemies: Count age by estimated postconception date (not by actual delivery date) for 1st-90d


CSF cell count, GS, Cx
===0-7 Days===
 
''For all infants (toxic and well-appearing)''
CXR (only if resp sx)
 
Stool testing (if diarrhea present)
 
|
Admit
 
Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg)


{| class="wikitable"
|-
|-
|  
| '''Child Appearance'''
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol)
| '''Work Up'''
 
| '''Treatment'''
<br>SBI incidence of ill appearing: 13%–21%
| '''Disposition & Follow-up'''
 
| '''Comments'''
if not ill appearing: &lt;5%
 
<br>
 
| Same as for neonates
|  
Discharge if:
 
1. WBC &lt;15K but &gt;5K and &lt;20% bands
 
2. UA negative
 
Admit and perform LP if above are not met
 
Treat with CTX 50mg/kg (if CSF normal), 100mg/kg (if signs of meningitis)
 
|-
|-
| '''Temperature ≥38°'''
'''Toxic or Well'''
|  
|  
57d-6mo, ≥38
*CBC
 
*Blood cultures
Non-UTI SBI incidence is estimated to be negligible
*[[Urinalysis]], Urine culture
 
*[[LP]]-CSF
<span class="Apple-style-span" style="line-height: 17px">UTI is 3%–8%</span>&nbsp;
*[[CXR]]
 
*+/- Stool studies (if diarrhea)
<br>
 
|  
|  
UA and Ucx alone
{{Pediatric fever antibiotics 0-28)}}
| Admit
| SBI incidence
*Ill appearing: 13%–21%
*Not ill appearing: <5%
|}


OR
{{Pediatric fever acyclovir indications}}


treat 57-90d using Philadelphia Protocol
Note:
*CXR is optional if no resp sx and another source identified
*LP is necessary even if another source identified due to immature blood-brain barrier
*Do not give ceftriaxone to children <28d as may cause hyperbilirubinemia


|  
===8-21 Days<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>===
Discharge if negative
*For toxic infants, treat for sepsis and admit
*For well-appearing infants, see below algorithm
[[File:Peds fever 8-21 days (2.0).png|8-21 day algorithm]]


Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient
===22-28 Days<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>===
*For toxic infants, treat for sepsis and admit
*For well-appearing infants, see below algorithm
[[File:Peds fever 22-28 days (2.0).PNG]]


Admit and tx with CTX if fail criteria for d/c
===29-60 Days<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>===
*For toxic infants, treat for sepsis and admit
*For well-appearing infants, see below algorithm
[[File:Peds fever 29-60 (2.0).PNG]]


===60 Days - 36 Months<ref>Jaskiewicz, J.A., McCarthy, C.A., Richardson, A.C., White, K.C., Fisher, D.J., Powell, K. R., et al. (1994). Febrile infants at low risk for serious bacterial infection-an appraisal of the Rochester criteria and implications for management. Pediatrics 94(3), 390-396.</ref>===
{| class="wikitable"
|-
|-
|  
| '''Appearance'''
57d-6mo, ≥39 (102.2)
| '''Work Up'''
 
| '''Treatment'''
SBI incidence is estimated &lt;1%;
| '''Disposition & Follow-Up'''
 
non-UTI SBI incidence is estimated to be negligible.
 
UTI is 3%–8%
 
|  
UA and Ucx alone
 
OR
 
UA and Ucx + CBC + blood cx
 
|  
:
 
Discharge if negative
 
Treat for UTI as above
 
If WBC&gt;15K&nbsp;consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr
 
If WBC&gt;20K&nbsp;consider CXR and CSF
 
|-
|-
| '''T≥38° + Toxic'''
|  
|  
&nbsp;6–36 mo
*CBC
 
*Blood cultures
Non-UTI SBI incidence is &lt;0.4%&nbsp;
*[[Urinalysis]], urine culture
 
*[[LP]]-CSF
UTI in girls ≤8%
*[[CXR]]^
 
UTI in boys (&lt;12 mo) ≤ 2%
 
Uncircumcised boys (1–2 y) remains 2%
 
|
UA and Ucx in:
 
(girls 6-24mo)
 
(circ 6-12mo)
 
(uncirc 6-24mo)
 
|  
|  
Discharge if negative
{{Pediatric fever antibiotics 90dy-36mo}}
 
| Admit
Treat for UTI as above as outpatient
 
|-
|-
| &gt;36mo
| '''T≥39°C + Well + Non-complete [[Prevnar]]'''
| No further w/u is routinely necessary
(No [[Prevnar]] or <4 weeks post 1st [[Prevnar]] dose)
| <br>
|}
 
Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d
 
== Harbor-UCLA Protocol  ==
 
=== 0-28dy  ===
 
{| style="width: 500px" cellspacing="1" cellpadding="1" border="1"
|-
| Child Appearance
| Evaluation
| Treatment
|-
|
Toxic or Well
|
#CBC
#Blood Cx
#UA, Ucx
#LP-CSF (cell count, GS, Cx)
#CXR (only if resp sx)  
|  
|  
#Admit
*[[Urinalysis]], Urine culture
##Cefotaxime 50-100 mg/kg
*CBC
##Ampicillin 100-200 mg/kg  
*+/- CXR
##Acyclovir 20 mg/kg^
| If WBC(+):
*[[Ceftriaxone]] 50mg-100mg/kg (also then consider [[blood culture]] and [[LP]], especially in <6mo old)
| Outpatient (24 hour follow-up)
|-
|-
| '''T≥39°C + Well + [[Prevnar]]'''
(2 [[Prevnar]] or ≥4 weeks post 1st [[Prevnar]] dose)
|  
|  
|}
*Urine workup (UA, urine culture) for:
 
**Circumcised males <6 months
=== 28dy-90dy  ===
**Uncircumcised males <12 months
 
**All females
{| style="width: 500px" cellspacing="1" cellpadding="1" border="1"
*+/- CXR
| Treat [[cystitis]] or [[pneumonia]] if postitive
| Outpatient (48hour follow up)
|-
|-
| Age Group
| '''T≥38-38.9°C + Well'''
| Evaluation
| Consider UA, CXR based on symptoms, etc
| Treatment
| Treat [[cystitis]] or [[pneumonia]] if positive
 
| Outpatient (48-72 hour follow-up)<ref>Baker, M.D., Bello, L.M., & Avner, J.R. (1993). Outpatient management without antibiotics of fever in selected infants. New England Jouranl of Medicine, 329(20), 1437-1441.</ref>
|-
|-
|  
|}
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol)
{{Pediatric fever CXR indications}}


<br>SBI incidence of ill appearing: 13%–21%  
*Non-UTI SBI incidence of <.4% in children >6 mo


if not ill appearing: &lt;5%
==Low Risk Lab Criteria==
''If low-risk criteria below not met, then perform the LP (if not done) and admit for inpatient antibiotics''<ref> Smitherman, H.F. & Macias, C.G. (2014). Evaluation and management of fever in the neonate and young infant (less than three months of age) [Electronic Version]. UpToDate,Teach, S.J., Kaplan, SL, Wiley, JF.</ref><ref>Dagan, R. Sofer, S., Phillip, M., & Shachak, E. (1988). Ambulatory care of febrile infants younger than 2 months of age classified as being at low risk for having serous bacterial infections. Journal of Pediatrics, 112(3), 355-360.</ref>
===CBC===
*WBC 5-15 /mm<sup>3</sup>
*Absolute Band count <1500 /mm<sup>3</sup>
*Procalcitonin ≤0.5 ng/mL
*ANC ≤4000/mm<sup>3</sup>
===Urinalysis===
*Clear
*Neg Nitrate and Leukocyte esterase
*WBC <10/high powered field
===CSF===
*Studies should include WBC, protein, glucose, Gram stain, and culture for bacteria. Consider viral studies (HSV).
====0-28 days====
*WBC: 0-22/mm<sup>3</sup>
*Protein: <100mg/dL
====>29 days====
*WBC 0-7/mm<sup>3</sup>
*Protein: 15-25mg/dL


<br>
==Additional Management==
 
===Initial Empiric Antibiotics for Well-Appearing Infants<ref>Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228 </ref>===
|
{| {{table}}
#CBC, blood Cx
| align="center" style="background:#f0f0f0;"|'''Suspected Infection Source'''
#UA, Ucx
| align="center" style="background:#f0f0f0;"|'''8-21 Days Old'''
#CSF cell count, GS, Cx
| align="center" style="background:#f0f0f0;"|'''22-28 Days Old'''
#CXR (only if resp sx)
| align="center" style="background:#f0f0f0;"|'''29-60 Days Old'''
#Stool testing (if diarrhea present)
|  
Discharge if:  
#WBC &lt;15K but &gt;5K and &lt;20% bands
#UA negative
 
Admit if:
#Above are not met
#Treat
##CTX 50mg/kg if CSF normal
##100mg/kg if signs of meningitis
|-
|-
|  
| [[UTI]]||
57d-6mo, ≥38
*[[Ampicillin]] IV or IM (150 mg/kg per day divided q8) AND either:
 
**[[Ceftazidime]] IV or IM (150 mg/kg per day divided q8) or
Non-UTI SBI incidence is estimated to be negligible
**[[Gentamicin]] IV or IM (4 mg/kg per dose q24)
 
||
|  
*[[Ceftriaxone]] IV or IM (50 mg/kg per dose q24)
UA and Ucx alone
||
 
*[[Ceftriaxone]] IV or IM (50 mg/kg per dose q24)
OR
*Oral options:
 
**[[Cephalexin]] 50-100 mg/kg per day QID or
treat 57-90d using Philadelphia Protocol
**[[Cefixime]] 8 mg/kg QD
 
|  
Discharge if negative
 
Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient
 
Admit and tx with CTX if fail criteria for d/c
 
|-
|-
|  
| No source identified
57d-6mo, ≥39 (102.2)  
||
 
*[[Ampicillin]] IV or IM (150 mg/kg per day divided q8) AND either:
SBI incidence is estimated &lt;1%;
**[[Ceftazidime]] IV or IM (150 mg/kg per day divided q8) or
 
**[[Gentamicin]] IV or IM (4 mg/kg per dose q24)
non-UTI SBI incidence is estimated to be negligible.
||
 
*[[Ceftriaxone]] IV or IM (50 mg/kg per dose q24)
UTI is 3%–8%
||
 
*[[Ceftriaxone]] IV or IM (50 mg/kg per dose q24)
|  
UA and Ucx alone
 
OR
 
UA and Ucx + CBC + blood cx
 
|  
:
 
Discharge if negative
 
Treat for UTI as above
 
If WBC&gt;15K&nbsp;consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr
 
If WBC&gt;20K&nbsp;consider CXR and CSF
 
|}
 
=== 90dy-36mo  ===
 
{| style="width: 500px" cellspacing="1" cellpadding="1" border="1"
|-
|-
| Age Group
| Bacterial [[meningitis]]
| Evaluation
||
| Treatment
*[[Ampicillin]] IV or IM (300 mg/kg per day divided q6) AND
|-
*[[Ceftazidime]] IV or IM (150 mg/kg per day divided q8)
|
||
57d-6mo, ≥39 (102.2)  
*[[Ampicillin]] IV or IM (300 mg/kg per day divided q6) AND
 
*[[Ceftazidime]] IV or IM (150 mg/kg per day divided q8)
SBI incidence is estimated &lt;1%;
||
 
*Cephalosporin
non-UTI SBI incidence is estimated to be negligible.
**[[Ceftriaxone]] IV (100 mg/kg QD) or
 
**[[Ceftazidime]] IV (150 mg/kg QD)  
UTI is 3%–8%
*AND [[Vancomycin]] IV (60 mg/kg QD)
 
|
UA and Ucx alone
 
OR
 
UA and Ucx + CBC + blood cx
 
|
:
 
Discharge if negative
 
Treat for UTI as above
 
If WBC&gt;15K&nbsp;consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr
 
If WBC&gt;20K&nbsp;consider CXR and CSF
 
|-
|  
&nbsp;6–36 mo
 
Non-UTI SBI incidence is &lt;0.4%&nbsp;
 
UTI in girls ≤8%
 
UTI in boys (&lt;12 mo) ≤ 2%
 
Uncircumcised boys (1–2 y) remains 2%
 
|  
UA and Ucx in:
 
(girls 6-24mo)  
 
(circ 6-12mo)  
 
(uncirc 6-24mo)
 
|
Discharge if negative
 
Treat for UTI as above as outpatient
 
|-
| &gt;36mo
| No further w/u is routinely necessary
| <br>
|}
|}


Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d
{{Acetaminophen pediatric dosing chart}}
 
== See Also  ==


*[[UTI (Peds)]]  
==See Also==
*[[Sepsis (Peds)]]  
*[[Acute fever]]
*[[Meningitis (Peds)]]  
*[[Fever of unknown origin (peds)]]
*[[Febrile Seizure]]
*[[Urinary tract infection (peds)]]  
*[[Sepsis (peds)]]  
*[[Meningitis (peds)]]  
*[[Febrile seizure]]
*[[PECARN Febrile Infant]]


== Source  ==
==External Links==
*[http://www.pemed.org/blog/2011/10/9/fever-of-unknown-source-part-1.html PEM ED Algorithm for Pediatric Fever]
*[http://ddxof.com/pediatric-fever/ DDxOf: Pediatric Fever]


Tintinalli
==References==
<references/>


[[Category:Peds]]
[[Category:Pediatrics]]
[[Category:ID]]

Latest revision as of 16:46, 15 March 2023

Background

  • Fever accounts for 30% of pediatric visits
  • Children <3 months are immunocompromised (e.g. poor opsonization, poor IgG response to encapsulated bacteria, macrophage and neutrophil dysfunction, bone marrow insufficiency)

Epidemiology and Risk

Age 0-14 days 14-28 days 28-60 days (pre vaccine) 28-60 days (post vaccine) 60-90 days > 90 days
Meningitis/SBI Prevalence 1/10 1/20 1/100 1/1000 1/1000-10,000 > 1/10,000
  • Serious bacterial illness (SBI) includes UTI, meningitis, pneumonia, bacteremia
  • 7% of patients <2 years old with fever have pneumonia, however the etiology (viral/bacterial) or even the presence of pneumonia has low inter-observer reliability even among pediatric radiologists[1]
  • 4% Prevalence of UTI with common other sources of fever (OM, viral URI, etc)[2]
  • 0.3% of previously well children aged 3-36 months who have a fever without a source will develop significant sequelae, 0.03% will develop sepsis or meningitis[3]

Concomitant Respiratory Viral Infection

  • Relatively high coincidence of RSV, enterovirus, and paraflu with bacteremia (and UTIs), so positive lab test for these viruses should not change testing and management plan[4]
    • RSV+ neonates aged 0-28 days, 3.7% were bactremic (and 6.1% had UTIs)
    • RSV+ infants aged 29-60 days, (5.5% had UTIs)
  • There is a low coincidence of influenza with SBI, so postivie lab test for this virus may change testing and management plan (i.e. lower risk of concurrent bacterial illness)[5]

Clinical Features

  • Febrile
    • Defined as temperature ≥38°C (100.4°F).
    • Peripheral temperature is not clinically accurate and central measurements are the preferred means of determining fever.
    • Parental report of confirmed fever at home (i.e. via thermometer), even with no fever in ED, has rates of SBIs high as 4.7% (0-28 day range)[6]

Differential Diagnosis

Pediatric fever

Evaluation & Management

  • Preemies: Count age by estimated postconception date (not by actual delivery date) for 1st-90d

0-7 Days

For all infants (toxic and well-appearing)

Child Appearance Work Up Treatment Disposition & Follow-up Comments
Temperature ≥38°

Toxic or Well

  • CBC
  • Blood cultures
  • Urinalysis, Urine culture
  • LP-CSF
  • CXR
  • +/- Stool studies (if diarrhea)
 Admit SBI incidence
  • Ill appearing: 13%–21%
  • Not ill appearing: <5%

^Acyclovir if:

  • HSV infection in baby or mother
  • CSF pleocytoisis
  • Concerning skin lesions
  • Seizures
  • Abnormal LFTs

Note:

  • CXR is optional if no resp sx and another source identified
  • LP is necessary even if another source identified due to immature blood-brain barrier
  • Do not give ceftriaxone to children <28d as may cause hyperbilirubinemia

8-21 Days[7]

  • For toxic infants, treat for sepsis and admit
  • For well-appearing infants, see below algorithm

8-21 day algorithm

22-28 Days[8]

  • For toxic infants, treat for sepsis and admit
  • For well-appearing infants, see below algorithm

Peds fever 22-28 days (2.0).PNG

29-60 Days[9]

  • For toxic infants, treat for sepsis and admit
  • For well-appearing infants, see below algorithm

Peds fever 29-60 (2.0).PNG

60 Days - 36 Months[10]

Appearance Work Up Treatment Disposition & Follow-Up
T≥38° + Toxic Admit
T≥39°C + Well + Non-complete Prevnar

(No Prevnar or <4 weeks post 1st Prevnar dose)

If WBC(+): Outpatient (24 hour follow-up)
T≥39°C + Well + Prevnar

(2 Prevnar or ≥4 weeks post 1st Prevnar dose)

  • Urine workup (UA, urine culture) for:
    • Circumcised males <6 months
    • Uncircumcised males <12 months
    • All females
  • +/- CXR
 Treat cystitis or pneumonia if postitive Outpatient (48hour follow up)
T≥38-38.9°C + Well Consider UA, CXR based on symptoms, etc Treat cystitis or pneumonia if positive Outpatient (48-72 hour follow-up)[11]
  • Consider CXR for:
    • Respiratory symptoms
    • Fever >48 hrs
    • Tachypnea
    • Hypoxia
  • Non-UTI SBI incidence of <.4% in children >6 mo

Low Risk Lab Criteria

If low-risk criteria below not met, then perform the LP (if not done) and admit for inpatient antibiotics[12][13]

CBC

  • WBC 5-15 /mm3
  • Absolute Band count <1500 /mm3
  • Procalcitonin ≤0.5 ng/mL
  • ANC ≤4000/mm3

Urinalysis

  • Clear
  • Neg Nitrate and Leukocyte esterase
  • WBC <10/high powered field

CSF

  • Studies should include WBC, protein, glucose, Gram stain, and culture for bacteria. Consider viral studies (HSV).

0-28 days

  • WBC: 0-22/mm3
  • Protein: <100mg/dL

>29 days

  • WBC 0-7/mm3
  • Protein: 15-25mg/dL

Additional Management

Initial Empiric Antibiotics for Well-Appearing Infants[14]

Suspected Infection Source 8-21 Days Old 22-28 Days Old 29-60 Days Old
UTI
  • Ampicillin IV or IM (150 mg/kg per day divided q8) AND either:
No source identified
  • Ampicillin IV or IM (150 mg/kg per day divided q8) AND either:
Bacterial meningitis
  • Ampicillin IV or IM (300 mg/kg per day divided q6) AND
  • Ceftazidime IV or IM (150 mg/kg per day divided q8)
  • Ampicillin IV or IM (300 mg/kg per day divided q6) AND
  • Ceftazidime IV or IM (150 mg/kg per day divided q8)

Acetaminophen Pediatric Dosing Chart

Weight (kg) Weight (lbs) Age Dosage (mg)
3-4 6-11 0-3 mo 40
5-7 12-17 4-11 mo 80
8-10 18-23 1-2 y 120
11-15 24-35 2-3 y 160
16-21 36-47 4-5 y 240
22-26 48-59 6-8 y 320
27-32 60-71 9-10 y 400
33-43 72-95 11 y 480
Dosage can be given q6 hours

See Also

External Links

References

  1. ↑ ACEP's Clinical Policy on Pediatric Fever. Clinical Policy for Children Younger Than Three Years Presenting to the Emergency Department With Fever. Annuals of Emergency Medicine 2003 42. 530-545
  2. ↑ ACEP's Clinical Policy on Pediatric Fever. Clinical Policy for Children Younger Than Three Years Presenting to the Emergency Department With Fever. Annuals of Emergency Medicine 2003 42. 530-545
  3. ↑ ACEP's Clinical Policy on Pediatric Fever. Clinical Policy for Children Younger Than Three Years Presenting to the Emergency Department With Fever. Annuals of Emergency Medicine 2003 42. 530-545
  4. ↑ Greenes, D.S.M., & Harper, M. B.M. (1999). Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatric Infectious Disease Journal, 18(3), 258-261.
  5. ↑ Greenes, D.S.M., & Harper, M. B.M. (1999). Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatric Infectious Disease Journal, 18(3), 258-261.
  6. ↑ Serious bacterial infections in neonates presenting afebrile with history of fever Ramgopal S, Walker LW, Tavarez MM, et al. Pediatrics. 2019;144(2):e20183964.
  7. ↑ Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228
  8. ↑ Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228
  9. ↑ Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228
  10. ↑ Jaskiewicz, J.A., McCarthy, C.A., Richardson, A.C., White, K.C., Fisher, D.J., Powell, K. R., et al. (1994). Febrile infants at low risk for serious bacterial infection-an appraisal of the Rochester criteria and implications for management. Pediatrics 94(3), 390-396.
  11. ↑ Baker, M.D., Bello, L.M., & Avner, J.R. (1993). Outpatient management without antibiotics of fever in selected infants. New England Jouranl of Medicine, 329(20), 1437-1441.
  12. ↑ Smitherman, H.F. & Macias, C.G. (2014). Evaluation and management of fever in the neonate and young infant (less than three months of age) [Electronic Version]. UpToDate,Teach, S.J., Kaplan, SL, Wiley, JF.
  13. ↑ Dagan, R. Sofer, S., Phillip, M., & Shachak, E. (1988). Ambulatory care of febrile infants younger than 2 months of age classified as being at low risk for having serous bacterial infections. Journal of Pediatrics, 112(3), 355-360.
  14. ↑ Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old Robert H. Pantell, Kenneth B. Roberts, William G. Adams, Benard P. Dreyer, Nathan Kuppermann, Sean T. O'Leary, Kymika Okechukwu and Charles R. Woods; Subcommittee On Febrile Infants Pediatrics July 2021, e2021052228; DOI: https://doi.org/10.1542/peds.2021-052228
Retrieved from "https://www.wikem.org/w/index.php?title=Pediatric_fever_of_uncertain_source&oldid=369127"